p.98 抽出テキスト

Committee. J Card Fail 2019;25:380–400. https://doi.org/10.1016/j.cardfail. 2019.03.007 590. Denfeld QE, Jha SR, Fung E, Jaarsma T, Maurer MS, Reeves GR, et al. Assessing and managing frailty in advanced heart failure: an International Society for Heart and Lung Transplantation consensus statement. J Heart Lung Transplant 2024;43:1–27. https://doi.org/10.1016/j.healun.2023.09.013 591. Baudry G, Girerd N, Cikes M, Crespo-Leiro MG, Damman K, Delmas C, et al. Knowledge and application of ESC/HFA Guidelines in the management of advanced heart failure. Eur J Heart Fail 2024;27:1126–35. https://doi.org/ 10.1002/ejhf.3530 592. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009;28:535–41. https://doi.org/10.1016/j.healun.2009. 02.015 593. Samman-Tahhan A, Hedley JS, McCue AA, Bjork JB, Georgiopoulou VV, Morris AA, et al. INTERMACS profiles and outcomes among non-inotrope-dependent outpatients with heart failure and reduced ejection fraction. JACC Heart Fail 2018;6:743–53. https://doi.org/10.1016/j.jchf. 2018.03.018 594. Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2023;25:457–68. https://doi.org/10.1002/ejhf. 2814 595. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail 2019;21:1064–78. https://doi.org/10.1002/ ejhf.1557 596. Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, et al. Treatments targeting inotropy. Eur Heart J 2019;40:3626–44. https:// doi.org/10.1093/eurheartj/ehy600 597. Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy. JACC Heart Fail 2021;9:518–27. https://doi. org/10.1016/j.jchf.2021.04.005 598. Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock DD, et al. Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis. JACC Heart Fail 2018;6:757–67. https://doi. org/10.1016/j.jchf.2018.03.019 599. Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 2003;145:324–9. https://doi.org/10.1067/mhj.2003.50 600. Timoteo AT, Mano TB. Efficacy of peritoneal dialysis in patients with refractory congestive heart failure: a systematic review and meta-analysis. Heart Fail Rev 2023;28:1053–63. https://doi.org/10.1007/s10741-023-10297-3 601. Wang MJ, Zheng YM, Jin HX. Ultrafiltration for patients with acute decompensated heart failure: a systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28029. https://doi.org/10.1097/MD.0000000000028029 602. Arabia FA, Murray CF, Cantor R, Deng L, Gopalan R, Amabile O, et al. Heart transplant outcomes after total artificial heart. Transplant Proc 2023;55: 1664–73. https://doi.org/10.1016/j.transproceed.2023.05.020 603. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan MM, et al. 2019 EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg 2019;56:230–70. https://doi.org/10. 1093/ejcts/ezz098 604. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 2022;328:1233–42. https://doi.org/10.1001/jama.2022.16197 605. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device—final report. N Engl J Med 2019;380:1618–27. https://doi.org/10.1056/NEJMoa1900486 606. Schmitto JD, Shaw S, Garbade J, Gustafsson F, Morshuis M, Zimpfer D, et al. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. Eur Heart J 2024;45:613–25. https://doi.org/ 10.1093/eurheartj/ehad658 607. Numan L, Schramm R, Oerlemans M, van der Kaaij NP, Aarts E, Ramjankhan FZ, et al. Survival after HeartMate 3 left ventricular assist device implantation: real-world data from Europe. ESC Heart Fail 2023;10:2754–6. https://doi.org/10.1002/ehf2.14444 608. Jorde UP, Saeed O, Koehl D, Morris AA, Wood KL, Meyer DM, et al. The Society of Thoracic Surgeons Intermacs 2023 annual report: focus on magnetically levitated devices. Ann Thorac Surg 2024;117:33–44. https://doi. org/10.1016/j.athoracsur.2023.11.004 609. Ben Gal T, Ben Avraham B, Milicic D, Crespo-Leiro MG, Coats AJS, Rosano G, et al. Guidance on the management of left ventricular assist device (LVAD)-supported patients for the non-LVAD specialist healthcare provider: executive summary. Eur J Heart Fail 2021;23:1597–609. https://doi.org/10. 1002/ejhf.2327 610. Mehra MR, Netuka I, Uriel N, Katz JN, Pagani FD, Jorde UP, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. JAMA 2023;330: 2171–81. https://doi.org/10.1001/jama.2023.23204 611. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435–43. https://doi.org/10.1056/ NEJMoa012175 612. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 2017;376:440–50. https://doi.org/10.1056/NEJMoa1610426 613. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 2015;66:1747–61. https://doi. org/10.1016/j.jacc.2015.07.075 614. Knosalla C, Farber G, Rieth AJ, Wachter R, Placzek M, Albert W, et al. Rationale and design of the randomized ‘early ventricular assist device’—trial (VAD-DZHK3). ESC Heart Fail 2025;12:3731–40. https://doi.org/10.1002/ ehf2.15376 615. Karason K, Lund LH, Dalen M, Bjorklund E, Grinnemo K, Braun O, et al. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure: rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. Eur J Heart Fail 2020;22:739–50. https://doi. org/10.1002/ejhf.1773 616. Silver E, Argiro A, Murray SS, Korty L, Lin G, Pretorius V, et al. Genetic testing practices and pathological assessments in patients with end-stage heart failure undergoing heart transplantation and left ventricular assist device use. J Card Fail 2024;31:1039–47. https://doi.org/10.1016/j.cardfail.2024.09.015 617. Yamasaki T, Sanders SP, Hylind RJ, Milligan C, Fynn-Thompson F, Mayer JE Jr, et al. Pathology of explanted pediatric hearts: an 11-year study. Population characteristics and implications for outcomes. Pediatr Transplant 2024;28:e14742. https://doi.org/10.1111/petr.14742 618. Roberts WC, Salam YM. Frequency of congruence and incongruence between the clinical and morphological diagnoses in patients having orthotopic heart transplantations at the Baylor University Medical Center at Dallas from 1993 to 2020. Am J Cardiol 2021;156:114–22. https://doi.org/10.1016/j. amjcard.2021.06.027 619. Kim Y, Gunnarsdottir OB, Viveiros A, Reichart D, Quiat D, Willcox JAL, et al. Genetic contribution to end-stage cardiomyopathy requiring heart transplantation. Circ Genom Precis Med 2023;16:452–61. https://doi.org/10. 1161/CIRCGEN.123.004062 620. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2014;63: 1751–57. https://doi.org/10.1016/j.jacc.2014.01.053 621. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Ann Cardiothorac Surg 2018;7:3–11. https://doi.org/10.21037/acs.2017.09.18 622. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report—2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38:1056–66. https://doi.org/10.1016/j.healun. 2019.08.004 623. Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report—2021; focus on recipient characteristics. J Heart Lung Transplant 2021;40:1035–49. https://doi.org/10.1016/j.healun.2021.07. 015 624. Bakhtiyar SS, Sakowitz S, Mallick S, Curry J, Benharash P. Heart transplantation after donation after circulatory death: early United States experience. Ann Thorac Surg 2024;118:484–93. https://doi.org/10.1016/j.athoracsur. 2024.05.013 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026